Montelukast inhibits bronchoconstriction and gas exchange defects induced by leukotriene D4 challenge in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
Effects of salbutamol and enantiomers on allergen-induced asthmatic reactions and airway hyperreactivity Source: Eur Respir J 2005; 25: 864-872 Year: 2005
Bronchial hypersensitivity and acute bronchodilatory effect of salbutamol on methacholine-induced bronchoconstriction in asthmatics with excessive airway narrowing Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004
Effects of salbutamol on gas exchange abnormalities and sputum neutrophilia induced by adenosine 5‘-monophosphate (AMP) in mild asthma Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Source: Eur Respir J 2002; 20: 853-858 Year: 2002
Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids Source: Eur Respir J 2002; 20: 1364-1369 Year: 2002
Nebulized salbutamol through the ultrasonic nebulizer during sputum induction improves the bronchoprotection in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Fluticasone propionate attenuates platelet-activating factor-induced gas exchange defects in mild asthma Source: Eur Respir J 2002; 19: 872-878 Year: 2002
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
Inhaled racemic salbutamol may cause enhanced bronchial response to cold air in mild asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 105s Year: 2001
Formoterol protects against platelet-activating factor-induced effects in asthma Source: Eur Respir J 2004; 23: 71-75 Year: 2004
Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Rapid protective effect of inhaled fluticasone on airway hyperresponsiveness to AMP in patients with fixed airway obstruction due to asthma but not COPD Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
IPL576,092 reduces allergen-induced late asthmatic responses, sputum eosinophilia and airway hyperresponsiveness in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 104s Year: 2003
Bronchial hyperresponsiveness to methacholine/AMP and the bronchodilator response in asthmatic children Source: Eur Respir J 2011; 37: 800-805 Year: 2011
Effect of formoterol with or without budesonide in repeated low-dose allergen challenge Source: Eur Respir J 2009; 33: 747-753 Year: 2009
Acute reversal of allergen-induced airway hyperresponsiveness (AHR) by olodaterol is synergistically enhanced by tiotropium bromide Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice Source: Eur Respir J 2008; 32: 970-978 Year: 2008
Absence of sputum eosinophils in subjects with symptomatic asthma on inhaled budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 274s Year: 2002
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015